

Novel blood-based proteomic signatures across multiple neurodegenerative diseases

Robert Durcan¹, Amanda Heslegrave², Peter Swann³, Julia Goddard^{1,4}, Leonidas Chouliaras³, Alexander G Murley¹, George Savulich³, W Richard Bevan-Jones³, Owen Swann², Nicholas J Ashton^{5,6,7}, Kaj Blennow^{5,8}, William McEwan⁴, Henrik Zetterberg^{2,5,8,9,10,11}, James B Rowe^{1,12}, John T O'Brien³, Maura Malpetti^{1,4*}

1 University of Cambridge Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, Cambridge, CB2 0SZ, UK

2 UK Dementia Research Institute at UCL, London, WC1N 6BG, UK

3 Department of Psychiatry, University of Cambridge, Cambridge, CB2 0QQ, UK

4 UK Dementia Research Institute at University of Cambridge, Cambridge CB2 0XY, UK

5 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, S-431 80, Sweden

6 Banner Alzheimer's Institute and University of Arizona, Phoenix, AZ, USA

7 Banner Sun Health Research Institute, Sun City, AZ 85351, USA

8 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, S-431 80, Sweden

9 Department of Neurodegenerative Disease, UCL Institute of Neurology, London, WC1N 6BG, UK

10 Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China

11 Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA

12 Medical Research Council Cognition and Brain Sciences Unit, Cambridge, UK

*Correspondence to: Dr Maura Malpetti

Department of Clinical Neurosciences

University of Cambridge

Herchel Smith Building, Forvie Site

Robinson Way, Cambridge Biomedical Campus

Cambridge CB2 0SZ, UK

E-mail: mm2243@medschl.cam.ac.uk

Structured Abstract

INTRODUCTION: Blood-based biomarkers have the potential to support early and accurate diagnosis of neurodegenerative diseases, which is sensitive to molecular pathology and predictive of outcome. We evaluated a novel multiplex proteomic method in people with diverse neurodegenerative diseases.

METHODS: Serum from people with Alzheimer's disease (N=36), Lewy body dementia (N=34), frontotemporal dementia (N=36) and progressive supranuclear palsy (N=36) and age-matched controls (N=30) was analysed with the Nucleic acid Linked Immuno-Sandwich Assay (NULISA) central nervous system panel (~120 analytes) and inflammation panel (250 analytes). Biomarkers were compared across groups and included as predictors of survival.

RESULTS: The NULISA panels demonstrated high sensitivity and reliability for detecting multiple biomarkers across neurodegenerative disorders. There were condition-specific proteomic biomarkers, while NfL, CRH, CD276 and a data-driven inflammation pattern were significant transdiagnostic outcome predictors.

DISCUSSION: The sensitive NULISA multiplex approach supports differential diagnosis and target identification, with prognostically informative dementia-related biomarkers.

Abbreviations: neurofilament light chain (NfL / NEFL); Nucleic acid Linked Immuno-Sandwich Assay (NULISA); NULISA Protein Quantification (NPQ); Quanterix Single molecule array (SIMOA)

1. Background

As the field of neurodegenerative dementias and movement disorders moves into an era of disease modifying therapies, there is increasing need for provide early and accurate diagnoses. Current clinically used Alzheimer's disease (AD) biomarkers include cerebrospinal fluid (CSF) measures of A β 40/42 and phosphorylated tau, and amyloid- and tau-PET scans [1,2]. Both CSF and PET markers have high cost, infrastructure, and patient-tolerance barriers to implementation at scale in "real-world" settings. Seed amplification assays (SAA) using biofluids and skin biopsies are highly specific to distinct synucleinopathies [3] and tauopathies [4], but questions regarding clinical interpretation of potential "red herring" positive results from background non-causative co-pathology remain unanswered. The majority of evidence for SAA tools is based upon CSF and skin samples, which potentially limit their scalability to real-world settings, despite recent progress in plasma in Parkinson's disease [5].

Blood-based proteomic biomarkers offer a promising avenue for early and accurate diagnosis in neurodegenerative diseases that is scalable and deliverable in routine clinical care. Blood tests are very well tolerated, can be performed repeatedly for an individual, allowing assessment of test-retest reliability and temporal profiles through longitudinal assessment of disease trajectory, or in response to treatment.

Blood-based proteomic biomarkers have the potential to support diagnoses based on specific molecular pathologies of disease; or concomitant pathophysiological processes such as neuroinflammation and synaptic loss. The clinical and pathological heterogeneity seen within and between diagnostic groups may also be reflected in biomarker signals. Disease-specific fingerprints or disease-agnostic pathways may provide insights into mechanisms of disease and potential therapeutic targets. The revolution of blood-based biomarkers in dementia has been rapid in the last 5 years [6–12], despite the low concentration of many proteins in circulating

blood; and the limitation inherent in quantification of one marker or a small set of markers a time.

Recently, proteomic methods have been developed with high-sensitivity multiplex approaches. For example, the Nucleic acid-Linked Immuno-Sandwich Assay (NULISA), is a novel method of measuring many molecules in the human plasma and serum proteome, even to attomolar concentrations [13]. The NULISAseq “CNS Disease panel” analyses over 120 proteins associated with diverse neurodegenerative diseases. Results from this technique have been reported in Alzheimer’s Disease (AD) [14–17]. The NULISAseq “Inflammation Panel” analyses 250 proteins, many of which have been associated with the inflammatory responses observed neurodegenerative diseases [13].

We took a transdiagnostic approach to assess the utility of the NULISAseq method, with two principal aims. First, we compared NULISAseq assays of conventional biomarkers of neurodegeneration (phosphorylated tau isoforms, neurofilament light chain (NfL / NEFL) and glial fibrillary acidic protein (GFAP)) against results from the Quanterix Single molecule array (SIMOA) [8–11] with blood samples collected simultaneously from the same participants. Second, we integrated results from both NULISAseq CNS and Inflammatory panels to identify differentially expressed diagnostic and prognostic markers in people with well-defined common neurodegenerative diseases, including AD, Lewy body dementia (LBD), frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP).

2. Methods

2.1. Participants

Patient participants were recruited from specialist clinics for cognitive and movement disorders at the Cambridge University Hospitals NHS Trust and collaborating regional psychiatry and neurology services. We included participants with a clinical diagnosis that met clinical

consensus diagnostic criteria for MCI (n=20, amyloid biomarker positive) or AD-dementia (n=16) [18,19], probable or possible PSP (n=36) [20], FTD (n=36; 21 with behavioural variant FTD and 15 with primary progressive aphasia (PPA), consisting of 8 with non-fluent variant PPA and 7 with semantic variant PPA) [21,22], and LBD (n=34; 29 with dementia with Lewy bodies and 5 with Parkinson's disease dementia) [23]. As with previous studies from this patient participant cohort [24–26], we considered patients with a clinical diagnosis of AD and A β -positive MCI as a single cohort (AD/MCI+) as they represent a biological continuum. PET and/or CSF markers for amyloid were available to confirm the presence or absence of β -amyloid (interpreted as AD-pathology) in conditions with weak clinicopathological correlations and either high likelihood of a significant fraction with AD as main or co-pathology (LBD) or a high likelihood of clinical diagnostic false positives (amnestic MCI). All 20 MCI patients included in the study were amyloid-positive with PET imaging with the Pittsburgh compound B (PiB tracer at a cut-off of 19 centiloids [27]) and/or CSF Alzheimer's biomarkers at lumbar puncture (Amyloid-beta 1-42/40 ratio < 0.065 as recommended laboratory threshold from University College London Hospitals reference laboratory [28]). These participants were analysed together with those with early AD dementia as a single AD group (AD/MCI+). Of the LBD cohort, n=17/25 patients with PiB PET were amyloid-positive. Amyloid markers have not been assessed systematically for research purpose in patients with a clinical diagnosis of AD-dementia. We also included n=30 healthy controls with MMSE>26/30, absence of memory symptoms and no significant medical illnesses[29]. Exclusion criteria for both patient and healthy control cohorts included recent or current acute infection, major concurrent psychiatric illness, other severe physical illness, or a history of other significant neurological illness and/or autoimmune conditions. Participants underwent baseline clinical and neuropsychological assessment, including the revised Addenbrooke's

Cognitive Examination (ACE-R, 0-100 points). Survival data were collected up to census date of 24th of November 2024.

2.2. Blood sample collection and processing

Blood samples were obtained by venepuncture and collected in serum separation and EDTA tubes. They were centrifuged to isolate serum and plasma respectively, aliquoted and stored at $-70/80$ °C until further analyses.

Serum samples from all patients and controls were analysed with NULISA. The CNS panel (see Supplementary Table 1 for panel list), including A β peptides, phosphorylated tau forms, NfL (or 'NEFL' as from the panel nomenclature) and other markers of neurodegeneration, inflammation, and vascular health. In addition to the CNS panel, the samples were also analysed with the NULISAseq Inflammation Panel 250 (full list in Supplementary Table 2) for simultaneous analysis of 250 proteins associated with inflammatory and immune response processes (e.g. interleukins, chemokines, complement) with attomolar sensitivity to fg/ml units[13]. Sample and data analysis was performed according to kit manufacturer protocols, including Log₂ Transformation of the data and NULISA Protein Quantification (NPQ) on the logarithmic scale (Alamar Biosciences, Fremont, CA). Specifically, data is first normalised using internal and inter-plate controls. The data is then rescaled by multiplication with a factor of 10^4 . Following this, +1 is added to all values. The data is then log₂ transformed to make the data more symmetrical, forming a more normal distribution and accounting for the effects of outliers in subsequent statistical analyses. These values are defined as NULISA Protein Quantification (NPQ) units, which are on a logarithmic scale. Differences in NPQ can be interpreted as log₂ (fold change).

The majority (91.8%) of participants (n=158; Control=29, AD/MCI+=34 (MCI=19, AD=15), FTD=33 (bvFTD=18, PPA=15), LBD=31, PSP=31), also had paired plasma samples, that were analysed at the Clinical Neurochemistry Laboratory in Mölndal (Sweden). Plasma samples were thawed on wet ice, centrifuged at 500× g for 5 min at 4°C. Calibrators (neat) and samples (plasma: 1:4 dilution) were measured in duplicates. The plasma assays performed were the Quanterix Simoa Human Neurology 4-Plex E assay, measuring Aβ40, Aβ42, GFAP and NfL (Quanterix, Billerica, MA), p-tau231 (in-house Simoa assay) and the p-tau217 ALZpath assay, as previously described [6,11]. Plasma samples were analyzed at the same time using the same batch of reagents. A four-parameter logistic curve fit data reduction method was used to generate a calibration curve. Two control samples of known concentration of the protein of interest (high-control and low-control) were included as quality control. Intra-assay coefficients of variation were below 10%.

2.3. Statistical analysis

Analyses were performed using R (version 4.4.2). For descriptive statistics chi-square and analysis of variance tests compared variables between groups. Statistical analyses on blood-derived markers were carried out in three steps.

First, we compared NULISA CNS panel results on serum samples with Simoa assays on plasma samples from the same participants. Since NULISA NPQ values are log₂-transformed, we applied log₂ transformation to the absolute quantification values of plasma markers (as log₂(pg/mL + 1)). Following transformation, we performed Spearman's correlation analyses on like-for-like markers, including p-tau217, p-tau231, NfL and GFAP. Then, we ran group comparisons with Kruskal-Wallis tests, with Dunn's post-hoc tests, on NULISA single markers separately.

Second, we implemented Linear Models for Microarray and RNA-Seq Data (LIMMA models) to compare the differential protein expression on each panel, between diagnostic groups and controls. Results were displayed with volcano plots using colour schemes to highlight the markers that were significantly different between groups, considering uncorrected p values and after false discovery rate (FDR) correction for multiple comparisons. All LIMMA analyses included age and sex as covariates.

Third, we investigated the relationship between dementia-relevant markers on the CNS panel and survival. Survival status was available for all the patient participants who passed quality check for the CNS panel (n=141, 70 deceased and 71 still alive) at the census date. Survival analysis used Cox proportional hazards regression (R function `coxph`), including all CNS panel markers that were significantly different between controls and patients, with time from blood test to death as the moderating variable of interest. Age, sex and diagnosis group were added as covariates. We then applied a similar analysis in all the patients who passed quality check for the Inflammation panel (n=138 patients: 68 deceased and 70 still alive) , and included in the model all inflammation panel markers that were significantly different across all patients as compared to controls. See Supplementary Table 3 for demographic summaries of survival cohorts.

2.4.Data Availability

Anonymized processed data can be shared upon request to the corresponding author. Raw data may also be requested but are likely to be subject to a data transfer agreement with restrictions required to comply with participant consent and data protection regulations.

3. Results

3.1. Cohort characteristics

Participant demographics and clinical characteristics are described in Table 1. Patients with LBD were slightly older than controls and had the highest proportion of male participants. Participants with AD/MCI+ and PSP scored significantly higher on the ACE-R than other groups, while patients with LBD and FTD showed the lowest performance on average.

3.2. Quality control checks

NULISA markers were detected with high sensitivity in both CNS and Inflammation panels (94.1% and 97.3% target detectability, respectively). Two samples (1 control, 1 PSP) failed the quality check for the CNS panel and four samples (1 DLB, 1 nvPPA, 2 PSP) failed the quality check for the Inflammation panel. In one patient with PSP, both panels failed quality check. These sample failures were excluded from further analyses. On the main CNS markers (p-tau217, p-tau231, NfL and GFAP) we tested for associations with freezer storage time, as data collection spanned 10 years. Correlation analyses between NULISA CNS protein quantification and years of storage in $-70/-80$ °C freezers did not identify significant associations (See Supplementary Figure 1).

3.3. NULISA vs Simoa biomarker measurements

We compared NULISA serum-based markers with Simoa plasma-based markers. All principal like-for-like proteins significantly correlated (Figure 1A). Specifically, p-tau217 and NfL showed the strongest correlations ($\rho=0.798$ and $\rho=0.881$ respectively, $p<0.0001$), followed by GFAP ($\rho=0.762$, $p<0.0001$) and p-tau231 ($\rho=0.693$, $p<0.0001$).

3.4.NULISA CNS panel across diagnostic groups

Group comparisons on dementia-relevant single markers from the NULISA CNS panel revealed diagnostic differences (Figure 1B). Specifically, Kruskal Wallis Tests were significant across all 4 markers. Post hoc Dunn tests (considering adjusted p values) indicated that p-tau217 levels were significantly increased in patients with AD/MCI+ (AD > MCI+) and LBD as compared to controls, while p-tau231 levels were slightly increased also in patients with PSP. Levels of NfL were higher in all patient groups as compared to controls, while GFAP levels were increased especially in patients with AD/MCI+ and LBD and to a lower extent in patients with PSP.

Comparing each patient cohort with controls (Figure 2) including the whole CNS panel, p-tau epitopes (p-tau217, p-tau231, p-tau181) were significantly increased in AD/MCI+ and LBD. In patients with AD/MCI+, but not LBD, serum levels of MAPT were also significantly increased as compared to controls. Increased levels of serum NfL was the most significant marker in comparing FTD and PSP cohorts with controls, followed by multiple cytokines and chemokines. The homeostatic autophagy regulating scaffold protein (SQSTM1) was elevated in PSP versus controls and AD/MCI+, while Presenilin 1 (PSEN1), a key protein in amyloid- β clearance, was elevated in both FTD and PSP cohorts versus controls. PARK7 and PGK1 levels, important enzymes in glycolysis regulation, were increased in FTD versus controls. All patient groups showed lower levels of corticotropin-releasing hormone (CRH), than controls. This survived FDR correction in the comparison between patients with FTD and controls. See Supplementary Table 4 for all comparisons.

Next, the diagnostic groups were analysed against the AD/MCI+ group (Supplementary Figure 2). AD/MCI+ had significant higher levels of p-tau217, p-tau231, p-tau181, MAPT and pro-

neuropeptide Y (NPY) as compared to FTD and PSP cohorts. Comparing FTD and PSP, patients with PSP showed higher levels of inflammation-related markers, including IL7, CX3CL1, and periostin (POSTN) than FTD. In FTD, higher levels of fibroblast growth factor 2 (FGF2) were observed than in PSP. Compared to the AD/MCI+ cohort (Supplementary Figure 2), patients with LBD showed higher levels of neuropentraxins (NPTX1/2) than AD/MCI+, but these comparisons did not survive FDR correction.

3.5.CNS markers for predicting survival

For the NULISA CNS panel, we conducted survival analysis in two steps. First, we applied a model using the 8 markers (NfL, p-tau217, p-tau231, p-tau181, GFAP, CRH, PSEN1, and CXCL10) that were significantly different between all patients and controls at stringent FDR-corrected level (see Supplementary Figure 3 and Supplementary Table 5). We tested these 8 markers as predictors of interest for survival alongside days from blood test to death in a Cox proportional hazards regression. Age, sex and disease groups were included as covariates. We fitted the full model and performed backward stepwise selection, which compared the full model with reduced models based on the Akaike information criterion (AIC) until no further improvement in AIC is achieved excluding predictors. The model retained NfL, CRH and diagnosis as predictors in the final model. In this final model post stepwise selection, NfL levels were significantly associated with shorter time to death [hazard ratio 2.12 (1.44–3.15), $p=0.0017$]. CRH levels were inversely associated with time to death [hazard ratio 0.76 (0.60–0.96), $p=0.021$] (see Figure 3A). To illustrate the prognostic effect of NfL (Figure 3C) and CRH (Figure 3D), we plotted Kaplan-Meier curves dividing patients with high and low values of NfL and CRH, as separated by the median. These effects were also plotted by disease groups in Supplementary Figure 4.

Second, we repeated the analysis including all 24 markers that were significantly different between patients and controls, considering p-values uncorrected for multiple comparisons to capture the full variance of biomarker signatures (see Supplementary Figure 3 and Supplementary Table 5). We included all 24 CNS markers as predictors of interest for survival alongside days from blood test to death in a Cox proportional hazards regression with backward stepwise selection. Age, sex and disease groups were included as covariates. The final data-driven selected model included NfL, CRH, 2 additional CNS markers and diagnosis as significant predictors of survival. The 2 additional CNS predictors were PSEN1 [hazard ratio 0.28 (0.13-0.58), p=0.001], and PGK1 [hazard ratio 1.36 (1.11-1.67), p=0.003] (see Figure 3B, Supplementary Table 6).

3.6.NULISA Inflammation panel across diagnostic groups

Comparing each patient cohort with controls (Figure 4), increased levels of Amphiregulin (AREG) and CD276 (also known as B7-H3) were identified in LBD, FTD and PSP as compared to controls. Patients with FTD and PSP showed higher levels in multiple inflammation markers, while AD/MCI+ and LBD cohorts showed a more limited pattern of upregulated markers. Patients with AD/MCI+ showed increased GFAP levels, but this comparison did not survive FDR correction. Importantly, C-reactive protein levels, a commonly used clinical marker of non-specific systemic inflammation, did not show any significant differences between diagnostic groups and controls. See Supplementary Table 7 for all comparisons.

Comparing each patient group to the AD/MCI+ cohort (Supplementary Figure 5), patients with LBD showed similar levels of inflammation markers as AD/MCI+, with a larger number of markers being upregulated in LBD than AD/MCI+ when FDR correction was not considered. FTD and PSP cohorts had higher levels in several inflammation markers as compared to AD/MCI+, including Matrix metalloproteinase-9 (MMP9) and Hepatocyte Growth Factor (HGF). Comparing FTD and PSP, no marker was significantly different when FDR correction was considered.

3.7. Common patterns of inflammation across diseases

When comparing patients (across all groups) with controls, several markers from the NULISA inflammation panel were significantly increased in patients as compared to healthy volunteers. Considering FDR-corrected p values, these included AREG, CD276, Chemokine Ligand 7 (CCL7), GFAP, Interleukin-1 Receptor antagonist (IL1RN), Colony Stimulating Factor-1 (CSF1), Oncostatin-M (OSM), Colony-Stimulating Factor – 3 (CSF3), Cardiotrophin 1 (CTF1), Interleukin 17 A & F (IL17A-IL17F), and Thymic Stromal Lymphopoietin (TSLP). In contrast, Tumor Necrosis Factor Superfamily Member 9 (TNFSF9) was decreased in all patient groups. Considering uncorrected p-values, 45 additional markers were identified as increased in patients as compared to controls, including CD200, Interferon-alpha 1 (IFN α 1), NF-kappa-B essential modulator (NEMO), Interleukin-18 (IL-18), Interleukin-1-Beta (IL1 β), Lipocalin-2 (LCN2), Leukaemia Inhibitory Factor (LIF), Matrix Metalloproteinase-9 (MMP9), Programmed Cell Death 1 Ligand 2 (PD-L2), S100A12, S100A9, Tissue inhibitor of Metalloproteinases 2 (TIMP2), Tumor Necrosis Factor Receptor Superfamily Member 14 (TNFRSF14), Triggering Receptor Expressed On Myeloid Cells 2 (TREM2), Interleukin-6 (IL-6), Interleukin-22 and Interleukin-17A (IL-17A) (see Supplementary Figure 6 and Supplementary Table 8 for full list).

3.8. Inflammation markers for predicting survival

Similarly to statistical methods described in section 3.5, survival analysis on the NULISA Inflammation panel was conducted at two levels. First, we applied a conservative model with only those 12 markers that were significantly different between all patient groups and controls at stringent FDR-corrected level (AREG, CD276, CCL7, GFAP, IL1RN, CSF1, OSM, CSF3, CTF1, IL17A-IL17F, TSLP and TNFSF9 - see Supplementary Figure 6 and Supplementary Table 8). We included the 12 markers as predictors of interest for survival alongside days from blood test to death in a Cox proportional hazards regression. Age, sex and disease groups were included as covariates. As with the CNS panel in section 3.5, we fitted the full model and performed backward stepwise selection, which compared the full model with reduced models based on the Akaike information criterion (AIC) until no further improvement in AIC is achieved excluding predictors. The model selection retained CD276, AREG, and diagnosis as predictors in the final model. CD276 [hazard ratio 2.22 (1.25–3.95), $p=0.007$] levels were significantly associated with time to death (Supplementary Figure 5B). To illustrate this effect, we plotted Kaplan-Meier curves separating patients with high and low values of CD276, by the marker-specific median (Figure 5A).

Second, we repeated the analyses including all 57 markers that were significantly different between patients and controls, considering p values uncorrected for multiple comparisons to capture the full variance of biomarker signatures (see Supplementary Figure 6 and Supplementary Table 8). We included all 57 inflammation markers as predictors of interest for survival alongside days from blood test to death in a Cox proportional hazards regression with

backward stepwise selection. Age, sex and disease groups were included as covariates. The final data-driven selected model included 32 inflammation markers (of which, 25 were statistically significant predictors of survival), age, sex and diagnosis (Figure 5C, and Supplementary Table 9). Significant inflammatory predictors of survival included IL1 β , CD276, CXCL10 (IP-10), S100A12, IL17A, TREM2 and CD40, among others.

4. Discussion

Multiplex NULISA biomarkers demonstrated high sensitivity for detecting changes in serum protein levels across clinically and pathologically heterogeneous neurodegenerative disorders. There was high reliability and differential diagnostic sensitivity from the NULISA CNS panel, expanding previous evidence by (i) the inclusion of patients with sporadic FTD and PSP, and (ii) the prediction of survival. The NULISA Inflammation 250 panel detected changes in inflammatory patterns across multiple neurodegenerative diseases, with anti-inflammatory and pro-inflammatory changes, highlighting the complexity in interpreting cross-sectional plasma biomarkers in dynamic diseases.

Recent studies have shown the potential utility of the NULISA CNS panel to quantify dementia-relevant markers, including phosphorylated tau epitopes, NfL and GFAP, in blood of patients with MCI and/or AD [14–17], genetic FTD and LBD [15]. In our cohort, increased levels of serum NfL were identified across all patient groups as compared to controls, and were most elevated in the FTD and PSP cohorts. On the other hand, phosphorylated tau epitopes were the most significant markers in separating patients with AD and LBD from controls. These findings align with previous evidence with single-marker assays in similar cohorts [6–11], and suggest common AD co-pathology in the LBD cohort. Across all groups, we compared the NULISA CNS serum results with Simoa plasma assays for p-tau217, p-tau231, NfL and GFAP, finding strong correlations. This suggests the multiplex panel data can be as informative

as more targeted assays, showing good consistency with the advantage of quantifying additional markers, using either on plasma or serum samples. This aligns with and expands similar evidence in cohorts of healthy volunteers and patients with AD [14,16]. Importantly, the quantification of the CNS serum proteins in our cohort was not affected by the time they have been stored in freezers at -70/-80 °C.

We also demonstrate that dementia-relevant markers from the CNS panel are prognostic, against survival. Serum NfL levels were associated with subsequent faster decline and shorter time from blood sampling to death, over and above p-tau217, p-tau231 and GFAP levels, and over and above age and diagnosis. People with FTD and PSP show the strongest associations between NfL and survival. Serum and plasma NfL levels are promising markers for disease progression and may be useful trial endpoints in patients with FTD and PSP [7,30–35]. Here, survival rate was used to test for the prognostic utility of these markers as the high clinical heterogeneity across diagnostic groups makes it difficult to capture disease severity at the time of blood collection.

Beyond the common dementia-relevant markers previously described, the NULISA CNS panel in our cohort identified lower levels of CRH in all patient groups compared to controls. CRH is an important stress hormone that may be expected to be higher in diverse disease states. Impairment of the hypothalamic pituitary adrenal (HPA) axis has been long recognised in neurodegenerative disease. At post-mortem, diminished CRH is seen across brain regions in AD [36], while CSF cortisol is elevated in patients with AD versus controls [37]. One hypothesis for reduced levels of CRH in patients is endocrine insufficiency owing to hypothalamus neurodegeneration. Alternatively, high plasma cortisol is known to occur in AD, relating to worse hippocampal atrophy and clinical progression [38,39]; the resultant negative feedback loop may sufficiently explain the pattern of CRH being consistently higher in controls than patients. CRH is the only HPA axis protein examined in the NULISA CNS panel, thus

further investigations are required to clarify the biological underpinnings of this finding. Lower CRH levels were also associated with worse survival (Figure 3), with the strongest associations being in the LBD cohort (Supplementary Figure 4). In line with our findings, CRH has emerged as a biomarker of interest in LBD, but evidence to date has been CSF-based [40,41].

Stepwise selective survival modelling identified phosphoglycerate kinase-1 (PGK1) as a predictor of faster disease progression across this transdiagnostic cohort, while PSEN1 was associated with a longer survival time. PGK1 has an important role in metabolic function and glycolysis, dysregulation of which may potentiate a cycle of oxidative stress and neuroinflammation. This finding of PGK1 elevation may reflect a compensatory response to increased metabolic demand in patients. Treatment to boost PGK1 has shown favourable effects in models of amyotrophic lateral sclerosis (ALS) [42]. PSEN1 is a core component of the γ -secretase mediated process through which amyloid precursor protein is cleaved and excreted. PSEN1 being inversely associated with survival time may plausibly reflect failure of the homeostatic clearance system. The potential contributions of PSEN1 to neurodegeneration go beyond amyloid pathology however, as it has been identified as a potentiator of neuroinflammation and apoptosis [43,44].

Across the CNS and Inflammation panels, patients with FTD and PSP showed upregulation of many inflammation markers, as compared to controls and patients with AD. Specifically, we identified pro-inflammatory proteins oncostatin M (OSM), matrix metalloproteinase 9 (MMP9) and the potent chemo-attractant CCL7 to be elevated in PSP and FTD versus controls. We found significantly increased levels of the anti-inflammatory proteins CD276 and AREG in PSP, FTD and LBD versus controls. The anti-inflammatory IL1 receptor antagonist (IL1RN) and the neuroprotective hepatocyte growth factor (HGF) were elevated in FTD and PSP versus controls only. Although previous fluid markers confirmed abnormally high levels of

inflammation in patients with FTD and PSP (see [45] for review), they have been largely confined to CSF, small case reports, limited panels and/or single markers. Our recent study, using Meso-Scale Discovery assays on serum samples, identified a pattern of pro-inflammatory cytokines upregulated in 214 patients with FTD, PSP and related conditions [33]. This inflammatory pattern, including TNF- α , TNF-R1, CSF-1, IL-17A, IL-12, IP-10, IL-6 and others, differentiated patients (all syndromes) from controls and was associated with significantly lower survival over time. Importantly, proinflammatory cytokines were associated with microglial activation in frontal and brainstem regions, as quantified by TSPO PET. The NULISA Inflammation panel provides simultaneous quantification of a larger number of inflammation markers, with better detectability for specific targets than previously used technologies [13]. In our cohort, patients with PSP or FTD over-expressed proteomic markers of inflammatory/synaptic function as compared to controls and patients with AD. The degree of dysregulation across the landscape of inflammatory protein expression supports that FTD and PSP correlate with more peripheral markers of inflammation than in our cohort of AD. Further studies should investigate the inflammatory patterns on the AD spectrum with larger sample sizes, that allow the separation of patients in early and late stages of the disease. Several targets emerged as upregulated across diagnostic groups as compared to controls in our cohort. In particular, CD276, also known as B7-H3, is primarily an anti-inflammatory or immunosuppressive molecule. This immune checkpoint plays a complex role in the immune system, but its overall effect tends to inhibit immune responses, particularly in the context of cancer [46]. Although CD276 is predominantly anti-inflammatory, in non-small cell lung cancer, higher CD276 expression has been associated with increased numbers of CD8⁺ T cells and plasmacytoid dendritic cells [46]. In our cohort, higher levels of serum CD276 were associated with shorter survival, or time to death from blood sampling. However, the role of CD276 in non-cancerous neurological disorders has not been investigated before and further

studies would be needed to elucidate its role in these conditions. When investigating the prognostic values of inflammation markers on survival rates, 25 proteins were found to show significant associations. Shorter time to death was associated with higher levels of IL1 β , interleukin 15 receptor subunit alpha (IL15RA), AREG, Erythropoietin (EPO), CD276, C-C motif chemokine 13 (CCL13), NF-kappa-B essential modulator (NEMO / IKBKG), Interleukin-23 (IL23), C-X-C motif chemokine 10 (CXCL10), Osteopontin (SPP1), Interleukin-12 subunit beta (IL12B), Fibroblast growth factor 19 (FGF19), C-C motif chemokine 7 (CCL7), Interleukin-17A (IL17A), and OX-2 membrane glycoprotein (CD200). These display complex physiology with dynamic response to illness and injury but are intrinsically involved in neuro-inflammation and immune modulation. Meanwhile, the predictors of longer survival were Membrane cofactor protein (CD46), Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), Tumor necrosis factor receptor superfamily member 5 (CD40), Cardiotrophin-1 (CTF1), Programmed cell death 1 ligand 2 (PD-L2), Triggering receptor expressed on myeloid cells 1 (TREM1), TREM2, Eotaxin (CCL11) and Interleukin-17A |Interleukin-17F (IL17A/F). While also involved in the neuro-inflammatory response, these proteins are involved in apoptosis, tissue repair and cell survival. The relationship between a biomarker and disease trajectory is unlikely to be linear in such dynamic illnesses, so a static snapshot may not account for disease stage and/or severity. However, it is a testable hypothesis that precision medicine aimed at one or a combination of these potential immune targets may provide true disease modification within or across neurodegenerative diseases. Among other markers, IL1 β and IL15RA showed particularly strong predictive effects of shorter survival. These cytokines have been extensively described as involved in the pathophysiology of different neurodegenerative diseases [45,47–50].

This study has several limitations. First, patient groups were included and defined according to clinical diagnosis rather than definitive pathological confirmation, thus misdiagnosis and/ or co-pathologies may occur. In particular, amyloid markers were available only in patients with MCI and a portion of patients with LBD. As a result, AD pathology could not be consistently confirmed or excluded across the cohort. Second, blood-based inflammatory markers may capture comorbidities that are not directly linked to dementia, such as co-occurring inflammatory conditions or the use of specific anti-inflammatory medication. However, these are unlikely to occur in our cohort as the contributory clinical studies excluded recent systemic infections and concurrent autoimmune diseases. Of note, there was no transdiagnostic difference in C-reactive protein, a commonly used clinical marker of non-specific systemic inflammation. Third, our cohort was predominantly white/Caucasian reflecting the ethnicity distribution of the over 65-year-old population in the UK (94% ‘white’ in the 2021 national census). Further studies are needed to test the generalisation of results to other groups and to identify environmental, genetic and socioeconomic factors that might influence proteomic changes in dementia. Fourth, serum markers were measured at a single time point, whilst longitudinal studies would be needed to test-retest reliability and for disease-related dynamics over time. We have not accounted for disease stage or clinical severity at the time of blood collection, which may explain some of the heterogeneity seen across and within disease groups. Fifth, peripheral blood may not be reflective of the environment within the CNS, and patterns discovered may vary depending on blood brain barrier integrity, which varies across pathologies. Sixth, while there is mixed evidence of temporal stability of p-tau epitopes, NfL and GFAP, it remains to be seen if the remainder of the proteins highlighted by this multiplex approach are impacted by time-of-day and circadian rhythm or other factors such as posture, exercise, diet or glymphatic clearance in sleep [51–53]. Seventh, a substantial proportion (approximately half) of patients were still alive at the time of analysis so predictors of survival

time may be characterised only partially (Supplementary Table 3). Finally, it should be noted that the correlation analyses across analytical platforms were performed using two different sample types (serum for NULISA and plasma for Simoa), which may explain modest correlations for some of the markers.

In conclusion, we have shown that a multiplex approach offers consistent results compared to more targeted single molecule arrays, while simultaneously enabling a much broader scope of analysis. The NULISA CNS and Inflammation panels identify disease specific patterns of neurodegeneration and neuroinflammation. This unique disease fingerprint offers insight into disease specific pathogenesis, with potential inferences that this dysregulation may be deleterious and amenable to drug treatment. Treatment strategies that are highly efficacious at removing amyloid from the brain have shown only moderate clinical efficacy, thus it appears that alternative or indeed dual treatment strategies may be needed to tackle what are complex, multidimensional pathologies. This multiplex approach identified NfL, CRH, CD276 and inflammation signatures as useful prognostic markers across neurodegenerative diseases. Multiplex assay approach may offer scalable outcome measures for clinical trials in neurodegenerative diseases.

References

- [1] Dubois B, Von Arnim CAF, Burnie N, Bozeat S, Cummings J. Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants. *Alz Res Therapy* 2023;15:175. <https://doi.org/10.1186/s13195-023-01314-6>.
- [2] Therriault J, Schindler SE, Salvadó G, Pascoal TA, Benedet AL, Ashton NJ, et al. Biomarker-based staging of Alzheimer disease: rationale and clinical applications. *Nat Rev Neurol* 2024;20:232–44. <https://doi.org/10.1038/s41582-024-00942-2>.
- [3] Bellomo G, De Luca CMG, Paoletti FP, Gaetani L, Moda F, Parnetti L. α -Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. *Neurology* 2022;99:195–205. <https://doi.org/10.1212/WNL.0000000000200878>.
- [4] Vaughan DP, Fumi R, Theilmann Jensen M, Hodgson M, Georgiades T, Wu L, et al. Evaluation of Cerebrospinal Fluid α -Synuclein Seed Amplification Assay in Progressive Supranuclear Palsy and Corticobasal Syndrome. *Movement Disorders* 2024;mds.30019. <https://doi.org/10.1002/mds.30019>.
- [5] Kluge A, Schaeffer E, Bunk J, Sommerauer M, Röttgen S, Schulte C, et al. Detecting Misfolded α -Synuclein in Blood Years before the Diagnosis of Parkinson's Disease. *Movement Disorders* 2024;39:1289–99. <https://doi.org/10.1002/mds.29766>.
- [6] Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. *JAMA Neurol* 2024. <https://doi.org/10.1001/jamaneurol.2023.5319>.
- [7] Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, et al. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* 2022;93:651–8. <https://doi.org/10.1136/jnnp-2021-327788>.
- [8] Thijssen EH, Joie RL, Strom A, Fonseca C, Iaccarino L, Wolf A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *The Lancet Neurology* 2021;20:739–52. [https://doi.org/10.1016/S1474-4422\(21\)00214-3](https://doi.org/10.1016/S1474-4422(21)00214-3).
- [9] Rousset RZ, Claessen T, Van Harten AC, Lemstra AW, Pijnenburg YAL, Van Der Flier WM, et al. Performance of plasma p-tau217 and NfL in an unselected memory clinic setting. *Alz & Dem Diag Ass & Dis Mo* 2024;16:e70003. <https://doi.org/10.1002/dad2.70003>.
- [10] Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, Van Der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun* 2021;12:3400. <https://doi.org/10.1038/s41467-021-23620-z>.
- [11] Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathologica* 2021;141:709–24. <https://doi.org/10.1007/s00401-021-02275-6>.
- [12] VandeVrede L, Cho H, Sanderson-Cimino M, Wekselman F, Cobigo Y, Gorno-Tempini ML, et al. Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. *JAMA Neurol* 2025. <https://doi.org/10.1001/jamaneurol.2024.5017>.
- [13] Feng W, Beer JC, Hao Q, Ariyapala IS, Sahajan A, Komarov A, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. *Nature Communications* 2023;14:7238. <https://doi.org/10.1038/s41467-023-42834-x>.
- [14] Zeng X, Lafferty TK, Sehrawat A, Chen Y, Ferreira PCL, Bellaver B, et al. Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular

- and synaptic biomarkers in preclinical Alzheimer's disease. *Mol Neurodegeneration* 2024;19:68. <https://doi.org/10.1186/s13024-024-00753-5>.
- [15] Ashton NJ, Benedet AL, Di Molfetta G, Pola I, Anastasi F, Fernández-Lebrero A, et al. Biomarker Discovery in Alzheimer's and Neurodegenerative Diseases using Nucleic Acid-Linked Immuno-Sandwich Assay 2024. <https://doi.org/10.1101/2024.07.29.24311079>.
- [16] Ibanez L, Liu M, Beric A, Timsina J, Kohlfeld P, Bergmann K, et al. Benchmarking of a multi-biomarker low-volume panel for Alzheimer's disease and related dementia research. *Alzheimer's & Dementia* 2024;alz.14413. <https://doi.org/10.1002/alz.14413>.
- [17] Wang Y-T, Ashton NJ, Therriault J, Benedet AL, Macedo AC, Pola I, et al. Identify biological Alzheimer's disease using a novel nucleic acid-linked protein immunoassay. *Brain Communications* 2024;7:fcaf004. <https://doi.org/10.1093/braincomms/fcaf004>.
- [18] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's and Dementia* 2011;7:263–9. <https://doi.org/10.1016/j.jalz.2011.03.005>.
- [19] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on. *Alzheimer's & Dementia* 2011;7:270–9. <https://doi.org/10.1016/j.jalz.2011.03.008>.
- [20] Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria: MDS Clinical Diagnostic Criteria for PSP. *Mov Disord* 2017;32:853–64. <https://doi.org/10.1002/mds.26987>.
- [21] Gorno-Tempini ML, Hillis a E, Weintraub S, Kertesz a, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. *Neurology* 2011;76:1006–14. <https://doi.org/10.1212/WNL.0b013e31821103e6>.
- [22] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain* 2011;134:2456–77. <https://doi.org/10.1093/brain/awr179>.
- [23] McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor J-P, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. *Neurology* 2017;89:88–100. <https://doi.org/10.1212/WNL.0000000000004058>.
- [24] Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, et al. Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. *J Neurosci* 2019;39:7218–26. <https://doi.org/10.1523/JNEUROSCI.2574-18.2019>.
- [25] Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, et al. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. *Brain* 2020;143:1588–602. <https://doi.org/10.1093/brain/awaa088>.
- [26] Passamonti L, Rodríguez PV, Hong YT, Allinson KSJ, Williamson D, Borchert RJ, et al. ¹⁸F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. *Brain* 2017;aww340. <https://doi.org/10.1093/brain/aww340>.
- [27] Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's & Dementia* 2017;13:205–16. <https://doi.org/10.1016/j.jalz.2016.08.005>.

- [28] Keshavan A, O'Shea F, Chapman MD, Hart MS, Lunn MP, Paterson RW, et al. CSF biomarkers for dementia. *Pract Neurol* 2022;22:285–94. <https://doi.org/10.1136/practneurol-2021-003310>.
- [29] Bevan-Jones WR, Surendranathan A, Passamonti L, Rodríguez PV, Arnold R, Mak E, et al. Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. *BMJ Open* 2017;7:e013187. <https://doi.org/10.1101/525642>.
- [30] Rojas JC, Wang P, Staffaroni AM, Heller C, Cobigo Y, Wolf A, et al. Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. *Neurology* 2021;96:e2296–312. <https://doi.org/10.1212/wnl.00000000000011848>.
- [31] Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. *Ann Clin Transl Neurol* 2016;3:216–25. <https://doi.org/10.1002/acn3.290>.
- [32] Staffaroni AM, Quintana M, Wendelberger B, Heuer HW, Russell LL, Cobigo Y, et al. Temporal order of clinical and biomarker changes in familial frontotemporal dementia. *Nat Med* 2022;28:2194–206. <https://doi.org/10.1038/s41591-022-01942-9>.
- [33] Malpetti M, Swann P, Tsvetanov KA, Chouliaras L, Strauss A, Chikaura T, et al. Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration. *Brain* 2024:awae269. <https://doi.org/10.1093/brain/awae269>.
- [34] Mattsson N, Andreasson U, Zetterberg H, Blennow K, for the Alzheimer's Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. *JAMA Neurol* 2017;74:557. <https://doi.org/10.1001/jamaneurol.2016.6117>.
- [35] Wong YY, Wu C-Y, Yu D, Kim E, Wong M, Elez R, et al. Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis. *Parkinsonism & Related Disorders* 2022;101:119–28. <https://doi.org/10.1016/j.parkreldis.2022.06.004>.
- [36] Souza EBD, Whitehouse PJ, Price DL, Vale WW. Abnormalities in Corticotropin-releasing Hormone (CRH) in Alzheimer's Disease and Other Human Disorders. *Annals of the New York Academy of Sciences* 1987;512:237–47. <https://doi.org/10.1111/j.1749-6632.1987.tb24964.x>.
- [37] O'Brien JT, Ames D, Schweitzer I, Colman P, Desmond P, Tress B. Clinical and Magnetic Resonance Imaging Correlates of Hypothalamic–Pituitary–Adrenal Axis Function in Depression and Alzheimer's Disease. *Br J Psychiatry* 1996;168:679–87. <https://doi.org/10.1192/bjp.168.6.679>.
- [38] White S, Mauer R, Lange C, Klimecki O, Huijbers W, Wirth M, et al. The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment. *Alz & Dem Diag Ass & Dis Mo* 2023;15:e12463. <https://doi.org/10.1002/dad2.12463>.
- [39] Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, et al. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type. *Neurobiology of Aging* 2015;36:601–7. <https://doi.org/10.1016/j.neurobiolaging.2014.10.031>.
- [40] Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok-A-Hin YS, Lleó A, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease. *Nat Commun* 2023;14:5635. <https://doi.org/10.1038/s41467-023-41122-y>.

- [41] Fernandes Gomes B, Kumar A, Ashton NJ, Hall S, Stomrud E, Smith R, et al. Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders. *Brain Communications* 2024;6:fcae414. <https://doi.org/10.1093/braincomms/fcae414>.
- [42] Chaytow H, Carroll E, Gordon D, Huang Y-T, Van Der Hoorn D, Smith HL, et al. Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis. *eBioMedicine* 2022;83:104202. <https://doi.org/10.1016/j.ebiom.2022.104202>.
- [43] Czech C, Tremp G, Pradier L. Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. *Progress in Neurobiology* 2000;60:363–84. [https://doi.org/10.1016/S0301-0082\(99\)00033-7](https://doi.org/10.1016/S0301-0082(99)00033-7).
- [44] Bagaria J, Bagyinszky E, An SSA. Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene. *IJMS* 2022;23:10970. <https://doi.org/10.3390/ijms231810970>.
- [45] Bright F, Werry EL, Dobson-Stone C, Piguet O, Ittner LM, Halliday GM, et al. Neuroinflammation in frontotemporal dementia. *Nature Reviews Neurology* 2019;15:540–55. <https://doi.org/10.1038/s41582-019-0231-z>.
- [46] Durlanik S, Fundel-Clemens K, Viollet C, Huber HJ, Lenter M, Kitt K, et al. CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1. *Sci Rep* 2021;11:14849. <https://doi.org/10.1038/s41598-021-94360-9>.
- [47] Rentzos M, Zoga M, Paraskevas GP, Kapaki E, Rombos A, Nikolaou C, et al. IL-15 Is Elevated in Cerebrospinal Fluid of Patients With Alzheimer's Disease and Frontotemporal Dementia. *J Geriatr Psychiatry Neurol* 2006;19:114–7. <https://doi.org/10.1177/0891988706286226>.
- [48] Rentzos M, Rombos A. The role of IL-15 in central nervous system disorders: IL-15 and neurological disorders. *Acta Neurologica Scandinavica* 2012;125:77–82. <https://doi.org/10.1111/j.1600-0404.2011.01524.x>.
- [49] Beder N, Belkhef M, Leklou H. Involvement of inflammasomes in the pathogenesis of Alzheimer's disease. *Journal of Alzheimer's Disease* 2024;102:11–29. <https://doi.org/10.1177/13872877241283677>.
- [50] Valiukas Z, Tangalakis K, Apostolopoulos V, Feehan J. Microglial activation states and their implications for Alzheimer's Disease. *The Journal of Prevention of Alzheimer's Disease* 2025;12:100013. <https://doi.org/10.1016/j.tjpad.2024.100013>.
- [51] Della Monica C, Revell V, Atzori G, Laban R, Skene SS, Heslegrave A, et al. P-tau217 and other blood biomarkers of dementia: variation with time of day. *Transl Psychiatry* 2024;14:373. <https://doi.org/10.1038/s41398-024-03084-7>.
- [52] Orduña Dolado A, Stomrud E, Ashton NJ, Nilsson J, Quijano-Rubio C, Jethwa A, et al. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers. *Alz Res Therapy* 2024;16:132. <https://doi.org/10.1186/s13195-024-01503-x>.
- [53] Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, et al. Levels of Alzheimer's disease blood biomarkers are altered after food intake—A pilot intervention study in healthy adults. *Alzheimer's & Dementia* 2023;19:5531–40. <https://doi.org/10.1002/alz.13163>.

Acknowledgments

We thank our participant volunteers for their participation in this study, thank the National Institute for Health Research (NIHR) Cambridge BioResource centre staff, and the research nurses for their contribution, and the East Anglia Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) for help with subject recruitment.

For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising from this submission.

This work is licensed under a Creative Commons Attribution 4.0 International License.

Conflicts of interest

The authors have no conflicts of interest to report related to this work. Unrelated to this work, JTO has received honoraria for work as DSMB chair or member for TauRx, Axon, Eisai and Novo Nordisk, and has acted as a consultant for Biogen and Roche, and has received research support from Alliance Medical and Merck. JBR is a non-remunerated trustee of the Guarantors of Brain, Darwin College and the PSP Association (UK). He provides consultancy unrelated to the current work to Asceneuron, Astronautx, Astex, Curasen, CumulusNeuro, Wave, SVHealth, and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the Dementias Platform UK. M.M. has acted as a consultant for Astex Pharmaceuticals. W.M. is an academic co-founder and consultant to Trimtech Therapeutics and has a research grant funded by Takeda Pharmaceuticals. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures

in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). AH has served as a consultant for Quanterix and been a paid panel member for Lily.

Funding Sources

This study was co-funded by Race Against Dementia Alzheimer's Research UK (ARUK-RADF2021A-010); the Progressive Supranuclear Palsy Association (G124028); the Dementias Platform UK and Medical Research Council (MC_UU_00030/14; MR/T033371/1); the Wellcome trust (103838; 220258); the Cambridge University Centre for Parkinson-Plus (RG95450); CurePSP Research Grant (689-2024-01-Pipeline); the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312: the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care). This work is also supported by the UK Dementia Research Institute through UK DRI Ltd, principally funded by the Medical Research Council. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), The Galen and Hilary Weston Foundation, the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003).

Consent Statement

Participants with mental capacity gave their written informed consent to take part in the study according to the Declaration of Helsinki. For those who lacked capacity, their participation followed the personal consultee process in accordance with the UK law. The research protocols were approved by the National Research Ethics Service's East of England Cambridge Central Committee (REC references: 07/Q0102/3; 13/EE/0104).

Key Words: NULISA, multiplex assays, dementia, non-AD neurodegenerative diseases, blood-based biomarkers

Figure legends

Figure 1. Validation of the dementia-relevant single markers on the CNS panel: A) Associations between NULISA serum-based markers and Simoa plasma-based markers, considering like-for-like proteins. B) Group comparisons on dementia-relevant single markers from the NULISA CNS panel.




Figure 2. Comparisons between each patient group and controls on CNS markers. For each comparison, the panel on the right represents markers that are increased in patients as compared to controls, while the panel on the left represents markers reduced in patients. Orange dots represent comparisons with $p < 0.05$, and red dots with $p < 0.05$ corrected for multiple comparisons.




Figure 3. Prognostic markers on CNS panel. A) Final model by the backward stepwise selection on predictors in the survival analysis including 8 CNS markers (differentiating patients and controls at FDR-corrected level), age, sex and diagnosis. B) Final model selected on survival predictors including 24 CNS markers (differentiating patients and controls, *p*-uncorrected), age, sex and diagnosis. For each variable the hazard ratio on survival is plotted. C) and D) Kaplan–Meier Survival Curves of NfL and CRH, respectively, divided on the median of each marker C)




Figure 4. Comparisons between each patient group and controls on inflammation markers. For each comparison, the panel on the right represents markers that are increased in patients as compared to controls, while the panel on the left represents markers reduced in patients. Orange dots represent comparisons with $p < 0.05$, and red dots with $p < 0.05$ corrected for multiple comparisons.




Figure 5. Inflammation prognostic markers. A) Kaplan–Meier Survival Curves of CD276 divided on the median and B) final model by the backward stepwise selection on predictors in the survival analysis including 12 inflammatory markers (differentiating patients and controls at FDR-corrected level), age, sex and diagnosis. C) Final model selected on survival predictors including 57 inflammatory markers (differentiating patients and controls, *p*-uncorrected), age, sex and diagnosis. For each variable the hazard ratio on survival is plotted.




Table 1. Demographic and clinical characteristics for control and patient groups (= significant difference between patient group and controls in post hoc analysis).*

Group	N	Age	Sex (F/M)	ACE-R (score/100)
Control	30	68.3 (6.1)	14/16	-
AD/MCI+	36	71.8 (8.1)	16/20	79.0 (10.7)
LBD	34	73.9 (6.9)*	6/28	69.4 (14.8)
FTD	36	64.5 (7.8)	12/24	67.7 (20.4)
PSP	36	69.4 (6.7)	17/19	83.4 (10.2)
Group comparisons	-	F(4)=8.55, p<0.001	X ² (4)=9.22, p=0.06	F(3)=9.37, p<0.001